Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 33,061 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Early Phase 1 Interventional

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

NCT03845881
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Oxycodone, Placebo Oral Tablet
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Not applicable Interventional

A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.

NCT00605930
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Pyruvate, creatine, niacinamide, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 16, 2026, 5:43 PM EDT
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD).

NCT00760565
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
RO4905417, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Gainesville, Florida • Cincinnati, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 5:43 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

NCT07752407
View directory record Official record
Conditions
Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions
Vonoprazan, Placebo
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Mentor, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia

NCT00492336
View directory record Official record
Conditions
Schizophrenia
Interventions
rasagiline (Pharmacodynamics), Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Baltimore, Maryland • Catonsville, Maryland • Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)

NCT00280566
View directory record Official record
Conditions
Bipolar Mania, Bipolar Disorder
Interventions
Placebo, Ziprasidone Oral Capsule
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
73
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

NCT00942851
View directory record Official record
Conditions
Focal Dystonia
Interventions
Acetyl-Hexapeptide Topical Treatment, placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

NCT02799602
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
58
States / cities
Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men

NCT00549653
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
GW856553
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

NCT02602353
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Loxoprofen Pain Patch, Placebo Patch, No Treatment
Drug
Lead sponsor
Lead Chemical Co., Ltd.
Industry
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

NCT00677053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
TAK-442, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 80 Years
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

NCT00350337
View directory record Official record
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

NCT00131339
View directory record Official record
Conditions
Panic Disorder
Interventions
Cognitive behavioral therapy, D-cycloserine
Behavioral · Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Hartford, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2009 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250601
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
NGM282, Placebo
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Phoenix, Arizona • Coronado, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

NCT01846481
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
Interventions
RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Novel Blend of Plant Protein and Additional Ingredients on Resistance Training Adaptations

NCT06908811
View directory record Official record
Conditions
Resistance Exercise
Interventions
Novel Plant Protein Blend, Pea/Rice Protein Blend, Whey Protein, Carbohydrate Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 16, 2026, 5:43 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Angiotensin-(1-7) Cardiovascular Effects in Aging

NCT05301192
View directory record Official record
Conditions
Aging
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 16, 2026, 5:43 PM EDT
Terminated Phase 4 Interventional

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

NCT00079911
View directory record Official record
Conditions
Herpes Genitalis
Interventions
valacyclovir hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
3
States / cities
Altamonte Springs, Florida • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 16, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional Results available

Org 24448 to Treat Major Depression

NCT00113022
View directory record Official record
Conditions
Depression
Interventions
Org 24448, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01836029
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
VTX-2337, Carboplatin, Cisplatin, 5-fluorouracil, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
53
States / cities
Little Rock, Arkansas • Beverly Hills, California • Escondido, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 16, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Pilot Study of Creatine Monohydrate as an Augmenting Agent for ECT in Persons With Major Depressive Disorder

NCT04504253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine monohydrate, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 16, 2026, 5:43 PM EDT